UNIVERSITAS AIRLANGGA



Detail Article

Folia Medica Indonesiana

ISSN 0303-7932

Vol. 44 / No. 2 / Published : 2008-04

Order : 13, and page :127 - 131

Related with : Scholar   Yahoo!   Bing

Original Article :

Review article and clinical experience: varenicline (champix®) : a breakthrough for smoking cessation treatment (an α4ß2 nicotinic acethylcholine receptor partial agonist)

Author :

  1. Askandar Tjokroprawiro*1
  1. Diabetes and Nutrition Centre, Dr. Soetomo Teaching Hospital, Airlangga University School of Medicine, Jl Mayjen Mustopo 6-8, Surabaya

Abstract :

Tobacco is currently responsible for the death of one in ten adults in the world. Indonesia is also most prevalent for smoking with a total amount of smokers 62,800,000 people. Cigarette smoke contains gaseous compounds, one of which is nicotine, a compound that results in addiction. Nicotine produces neurochemical effects through six pathways. One of these is dopamine that produces the feeling of reward. Due its short half-life, withdrawal symptoms occur quickly, and results in relapses that reinforce the reward and satisfaction, which starts the addiction cycle. Varenicline (champix®), a selective a4ß2 nicotinic acethylcholine receptor (nAChR), is a drug for smoking cessation treatment. Varenicline is indicated for smokers (especially chain-smokers) in adults. The presence of varenicline is associated with lowered dopamine release level. Studies found that varenicline had an acceptable safety and well-tolerated. The majority of adverse events are reported to be of mild-to-moderate intensity. Health benefits of this drug starts immediately after cessation, and fifteen years afterwards, the CHD risk of the patient may be smaller to that of a non-smoker.

Keyword :

tobacco, cigarette smoke, nicotine, dopamine, smoking cessation,


References :

American Psychiatric Association,(2000) Diagnostic and Statistic Manual of Mental Disorders, 4th edn Text Revision (DSM-IV-TR) Arlington VA : American Psychiatric Association

Cahill, K, Stead, L, Lancaster, T,(2007) Nicotine receptor partial agonists for smoking cessation - : Cochrane Databased Syst Rev

Coe, JW, Brooks, PR, Vetelino, MG et al.,(2005) Varenicline: an lpha4ß2 nicotine receptor partials agonist for smoking cessation - : J Med Chem





Archive Article

Cover Media Content

Volume : 44 / No. : 2 / Pub. : 2008-04
  1. Tgf-β1 As The Trigger Of Pulp Fibroblast Proliferation
  2. Difference In Cyclooxygenase-2 (cox-2) Expression Between Low And High Grade Papillary Carcinoma In Human Bladder Cancer
  3. Detection Of Cytokeratin 19 Mrna In Blood As An Early Marker Of Micrometastatic Tumor Cells Of Nasopharyngeal Carcinoma Patients In Surabaya
  4. Pcr Technique Detection Of Chlamydia Trachomatis Dna Band Using Silver Nitrate Staining
  5. Change Of Cd4 Count, Hsp70 And Anti-hsp70 Levels In Hiv Patients
  6. Hiv/aids Prevalence In Surabaya, Indonesia
  7. Treatment Response And Acute Toxicity Evaluation Of 70 Gray Radiation In Nasopharyngeal Carcinoma Patients In Dr Soetomo Hospital, Surabaya
  8. Pharmacodynamic Effects Of Ligustroside Glycoside (a Cns Active Substance) Isolated From Fraxinus Graffithii Clarke Against Chemically Induced Seizures On Mice
  9. Management Of Acute Glomerulonephritis In A Child With Ischemic Stroke And Hypertensive Crisis
  10. Efficacy Of Orlistat Plus Diet Compared To Diet Alone In Reducing Body Weight And Body Mass Index
  11. Review Article: Pathogenesis Of Repeated Abortion In Polycystic Ovarian Syndrome (pcos)
  12. Review Article: Protein Calorie Malnutrition And Immune Response In Children
  13. Review Article And Clinical Experience: Varenicline (champix®) : A Breakthrough For Smoking Cessation Treatment (an α4ß2 Nicotinic Acethylcholine Receptor Partial Agonist)

Information index.php/JIPK/FMI